Enveda

Rounds and research, on one timeline

1. 2026-10-27
   Research

   Level 3 · Checked against existing evidence

   Across its runs, Enveda's document reviewer raised all 11 issues human reviewers found in 1,061 pages of batch records, and 7 they had not

   Batch-record review is required before a batch of a drug is released, and Anthropic's post says Enveda's manufacturing chemists had been spending up to 75% of their time on paperwork. This is the regulated-paperwork end of drug development, which rarely gets measured at all, and the yardstick here is what human reviewers caught on real records rather than a score on a benchmark.

   Timeline entry →enveda.com ↗

2. 2026-09-23Series E
   Round

   $311M

   For: move ENV-294 and ENV-308 into later-stage trials

   Toward the clinic

   Total raised since inception more than $845M.

   Lead · Catalio Capital Management ✓Durable Capital PartnersICONIQLightspeedSurveyor Capital (Citadel)T. Rowe PriceBaillie GiffordDigitalis VenturesAlderline GroupPremji Invest ✓FPV ✓True Ventures ✓Kinnevik ✓DimensionLifeforce CapitalLux Capital ✓

   On the deal: Alex Gorsky (General Partner at ICONIQ, Co-founder of Alderline Group, ICONIQ); George Petrocheilos (Co-founder and Managing Partner, Catalio Capital Management, joins the board)

   By this date the record held 2 research entries, highest level 5

   Announced by the company · biospace.com ↗On the timeline →

3. 2026-08-18
   Research

   Level 5 · Used in practice

   Enveda reports ENV-308, a pill built to mimic an exercise hormone, was well tolerated in 88 healthy volunteers

   Another drug Enveda found with its AI model reaches people, and the trial shows only that it is safe enough to keep testing. Leptin is an exploratory marker with no numbers given, the weight claims come from animals, and the readout is a company release, not a paper.

   Timeline entry →biospace.com ↗

4. 2026-07-24
   Research

   Level 5 · Used in practice

   Enveda reports an oral eczema pill cut skin scores 85% by day 42 in nine patients

   Nine patients, no placebo, company-reported: not proof it works. The release does not say how AI shaped this molecule.

   Timeline entry →biospace.com ↗

5. 2025-09-04Series D
   Round

   $150M

   For: advance ENV-294 and the pipeline

   Toward the clinic

   Company says the round took it to unicorn status, without a valuation figure; total funding $517M.

   Lead · Premji Invest ✓Baillie GiffordKinnevik ✓LingottoFPV ✓DimensionLux Capital ✓Peakline PartnersSocium VenturesLevel VenturesHenry KravisIA Ventures

   On the deal: Akshay Rai (Principal, Healthtech and Biotech, Premji Invest); Henry Kravis (Individual investor)

   Announced by the company · finance.yahoo.com ↗

6. 2025-02Series C extension
   Round

   Sanofi investment, amount not stated; brings Series C to $150M

   For: expand clinical pipeline and AI discovery

   Toward the clinicModels and platform

   Sanofi

   Announced by the company · biospace.com ↗

7. 2024-11-21Series C
   Round

   $130M

   For: reach clinical readouts in 2025-26 across programs

   Toward the clinic

   Total funding $360M after this round.

   Co-lead · Kinnevik ✓Co-lead · FPV ✓Baillie GiffordPremji Invest ✓LingottoLux Capital ✓DimensionHenry R. KravisTrue Ventures ✓Cresset PartnersThe Nature Conservancy

   On the deal: Christian Scherrer (Senior Investment Director and Head of Health and Bio, Kinnevik); Henry Kravis (Individual investor, Henry R. Kravis); James Anderson (CIO & Managing Partner, Lingotto Innovation Strategy, Lingotto); Pegah Ebrahimi (Managing Partner, FPV)

   Announced by the company · biospace.com ↗

8. 2024-06Series B extension
   Round

   $55M

   For: start clinical trials in late 2024 and early 2025

   Toward the clinic

   Added to the $119M Series B; BizWest puts total raised at about $230M.

   Premji Invest ✓LingottoMicrosoftThe Nature Conservancy

   Reported by BizWest · bizwest.com ↗

9. 2023-04Series B1
   Round

   $51M

   For: advance multiple programs toward the clinic

   Toward the clinic

   Equity added to the Dec 2022 round, taking it to $119M; the company release was not read.

   Henry Kravis

   On the deal: Henry Kravis (Individual investor)

   Reported by BizWest · bizwest.com ↗

10. 2022-12-21Series B
    Round

    $68M

    For: advance lead compounds to clinical candidates

    Toward the clinic

    $68M is equity and debt combined; company total $124M after the round.

    Lead · DimensionFPV ✓Jazz Venture Partners ✓True Ventures ✓Lux Capital ✓Two Sigma Ventures ✓Wireframe Ventures ✓Level VenturesAmino CollectiveAllen & CoPossible VenturesHummingbird Ventures ✓

    On the deal: Pegah Ebrahimi (Co-founder and Managing Partner, FPV); Zavain Dar (Co-founder and Managing Partner, Dimension)

    Announced by the company · biospace.com ↗

11. 2021-06-22Series A
    Round

    $51M

    For: advance its platform to discover and develop drug candidates from its chemical map of the natural world

    Models and platform

    Oversubscribed, per the company release.

    Lead · Lux Capital ✓Two Sigma Ventures ✓Hummingbird Ventures ✓Catalio Capital Management ✓Lifeforce CapitalMatthew De Silva (Notable Labs)True Ventures ✓Wireframe Ventures ✓Village GlobalChris Gibson (Recursion)

    On the deal: Chris Gibson (Existing investor); Matthew De Silva (Angel investor); Zavain Dar (Partner, Lux Capital)

    The investor's own page says · Lux Capital: 2021

    Announced by the company · biospace.com ↗

12. 2020-12-16Seed
    Round

    $4.9M

    For: grow its medicinal plant dataset, improve its technology and algorithms, and take its liver-fibrosis lead asset through preclinical development

    Data generationModels and platformToward the clinic

    Lead · True Ventures ✓Wireframe Ventures ✓Village GlobalChris Gibson (Recursion)

    On the deal: Chris Gibson (Angel investor); Rohit Sharma (Partner, True Ventures)

    Announced by the company · biospace.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →